ImageneBio, Inc. (IMA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -58.96M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 31.46M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-58.96M | (m) | (m) | $31.46M | (m) | (m) |
| 2026-03-31 | $-54.53M | (m) | (m) | $30.45M | (m) | (m) |
| 2025-12-31 | $-48.45M | $800.00K | (m) | $28.52M | (m) | -6056.38% |
| 2025-09-30 | $-68.06M | (m) | (m) | $27.78M | (m) | (m) |
| 2025-06-30 | $-44.47M | (m) | (m) | $19.14M | (m) | (m) |
| 2025-03-31 | $-51.54M | (m) | (m) | $24.95M | (m) | (m) |
| 2024-12-31 | $-58.97M | (m) | (m) | $30.88M | (m) | (m) |
| 2024-09-30 | $-68.36M | (m) | (m) | $40.57M | (m) | (m) |
| 2024-06-30 | $-75.46M | (m) | (m) | $48.41M | (m) | (m) |
| 2024-03-31 | $-78.13M | (m) | (m) | $53.74M | (m) | (m) |
| 2023-12-31 | $-75.42M | $9.16M | (m) | $59.65M | (m) | -823.33% |
| 2023-09-30 | $-68.62M | $13.95M | (m) | $61.02M | (m) | -491.89% |
| 2023-06-30 | $-67.00M | $19.17M | (m) | $65.21M | (m) | -349.52% |
| 2023-03-31 | $-69.46M | $17.55M | (m) | $65.53M | (m) | -395.83% |
| 2022-12-31 | $-70.90M | $15.62M | (m) | $64.32M | (m) | -453.99% |
| 2022-09-30 | $-53.00M | $30.39M | (m) | $61.02M | (m) | -174.42% |
| 2022-06-30 | $-49.64M | $27.73M | (m) | $55.54M | (m) | -179.04% |
| 2022-03-31 | $-41.38M | $30.89M | (m) | $51.43M | (m) | -133.94% |
| 2021-12-31 | $-34.14M | $30.98M | (m) | $47.11M | (m) | -110.18% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-44.52M | $9.19M | (m) | $44.85M | (m) | -484.22% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |